| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 0.06 | 500.0% |
| Total Income | 0.06 | 500.0% |
| Expenditure | 3.57 | 0.3% |
| PBT | — | |
| Net Profit | -3.40 | 11.1% |
| OPM | — | |
| NPM | — | |
| EPS | -0.08 | 75.8% |
SCIENTURE Reports Q1 2026 Revenue Increased 449% Y-o-Y
23 May 2026 · 23 May, 2:37 am
Summary
SCIENTURE HOLDINGS, INC. reported financial results for the three months ended March 31, 2026. Revenue increased by approximately 449% year-over-year to $56 thousand, driven by incremental product orders for ArbliTM. Gross profit increased by approximately 7900% year-over-year to $54 thousand, with gross margin expanding to approximately 95.6%. The company also secured $11.0 million in non-dilutive debt financing to accelerate growth and advance its R&D pipeline. The company anticipates the continued commercialization of ArbliTM and the planned launch of REZENOPYTM will have a meaningful impact on business performance during the second half of 2026.
Key Highlights
- 1
Revenue increased to approximately $56 thousand for the three months ended March 31, 2026, compared to approximately $10 thousand in the prior-year three-month period, representing an increase of approximately 449% year-over-year.
- 2
Gross profit increased substantially to approximately $54 thousand, compared to approximately $673 in the prior-year three-month period, representing an increase of approximately 7900% year-over-year.
- 3
Gross margin expanded to approximately 95.6% for the three months ended March 31, 2026, compared to approximately 6.6% in the prior-year three-month period.
- 4
The United States Patent and Trademark Office (USPTO) granted a third patent covering ArbliTM (losartan potassium) oral suspension, further strengthening the product’s intellectual property portfolio and extending expected market exclusivity through 2041.
- 5
The company secured $11.0 Million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of R&D pipeline.
- 6
The company received an Orange Book-listable patent for REZENOPYTM (naloxone HCl) nasal spray 10 mg, the highest-dose FDA-approved naloxone HCl nasal spray for emergency opioid overdose treatment.
- 7
Multiple commercial GPO agreements for REZENOPYTM were formalized, expanding access to over 5,000 healthcare institutions and reaching approximately 60% of the U.S. institutional market.
Management Comments
Narasimhan Mani
Our financial results for the quarter reflect the early progress of our commercialization strategy, with revenue increasing approximately 449% year-over-year to $56 thousand, gross profit increasing approximately 7900% year-over-year to $54 thousand, and gross margin expanding significantly to approximately 95.6%, compared to 6.6% in the prior-year period. The increase in revenue and gross margin reflects incremental product orders received for ArbliTM during the first quarter of 2026, following the significant initial launch quantity orders recorded in the fourth quarter of 2025. During the quarter, we experienced continued month-over-month growth in both prescriptions and units sold for ArbliTM. We are actively working to enhance our promotional and commercial activities around the product to further increase physician awareness and market penetration. We also continue to advance key commercial initiatives to support the planned launch of REZENOPYTM. Our sales force is scheduled to begin operations on June 1, 2026, targeting key accounts and purchasing organizations, and we have also successfully secured key GPO contracts that we believe will support broad commercial access and accelerate adoption following launch. Together, we believe the continued commercialization of ArbliTM and the anticipated launch of REZENOPYTM will have a meaningful impact on our business performance during the second half of 2026
Shankar Hariharan
In addition, we recently secured $11.0 million through a non-dilutive debt financing transaction that we believe significantly strengthens our capital position and provides important financial flexibility as we continue scaling our commercial operations. We believe this financing will serve as a catalyst to help position the Company toward anticipated profitability in 2027, while also supporting the continued growth of our commercial product portfolio and the progression of our R&D pipeline.
Informational and educational content only. Not investment advice.